Gene therapy for wet age-related macular degeneration in second eye
Part of Brain & nervous system, Eyes & vision clinical trials.
This study tests a one-time gene therapy injection (ixoberogene soroparvovec) in the second eye of people with wet age-related macular degeneration who have already responded well to anti-VEGF injections. The goal is to see if this gene therapy can help preserve or improve vision in that eye.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 50 years or older
- You have wet AMD (a form of macular degeneration) in both eyes caused by abnormal blood vessel growth
- Your vision in both eyes falls within specific ranges that the study defines
- You have previously responded well to anti-VEGF injections (standard wet AMD treatment) in at least one eye
- You are willing to use contraception during the study if you can become pregnant
- You can attend study visits and follow all study procedures
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a one-time gene therapy injection under the retina for people with wet age-related macular degeneration (AMD), which causes blurry vision from abnormal blood vessels. It aims to reduce the need for frequent eye injections by delivering a treatment that may help the eye produce its own medicine.
This trial tests a one-time gene therapy injection (IXO-vec) for people with wet age-related macular degeneration (nAMD). It aims to reduce the need for frequent eye injections by helping the eye make its own medicine to block the growth of harmful blood vessels.
This trial tests a one-time gene therapy injection (4D-150) for wet AMD. It might help reduce the need for frequent anti-VEGF eye injections by targeting the underlying cause of new blood vessel growth.
This study tests a new gene therapy called 4D-150 for people with wet age-related macular degeneration (AMD). It aims to reduce the need for frequent anti-VEGF injections by delivering a long-lasting treatment into the eye.
This trial tests a one-time gene therapy injection for wet AMD that may reduce the need for regular eye injections. It is for people who have already responded to anti-VEGF injections but want a longer-lasting treatment.
This trial tests an experimental gene therapy, OCU410, for people with geographic atrophy, an advanced form of dry AMD that causes blind spots in the center of vision. The study aims to see if this treatment can slow down the progression of the disease and help preserve remaining vision.
Hear when a new Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.